Clinical EPA/DHA Forte

Clinical EPA/DHA Forte

Clinical EPA/DHA Forte

Brand Natural Clinician
Unit Size 60 Enteric-coated fish oil soft gel capsules
Dosage Take one gel capsule twice daily on an empty stomach with 4 oz. of pure water. Physicians may adjust dosage upwards.

Product Information Sheet for Clinical EPA/DHA Forte

(0 reviews)  

This item is temporarily out of stock from the manufacturer and cannot be ordered at this time. As far as we know, this item has not been discontinued at this time, so please check back later or scroll to the bottom of the page to select an alternate (if one is available). You can also click the envelope icon to signup for an email notification.

Expected Resupply Date: Unknown

Targeted delivery enteric coated is nutritional support for many body structures and functions.

Clinical EPA/DHA Forte™, special enteric-coated delivery of high potency Omega-3 support is a revered dietary supplement use for professional healthcare practitioners. Unlike all other, less potent, regular fish oil products (liquids and softgels), this product is not available in retail locations.

. Fish oil contains active, Omega 3, essential fatty acids which are most abundant in the form of eicosapentaenoic acid (EPA, C20: 5n-3) and docosahexaenoic acid (DHA, C22: 6n-3). EPA and DHA are highly bioactive in comparison to precursors of Omega 3 fatty acids (alpha-linolenic acid ALA, found in flax, walnut, soy, oils and algae etc.) Precursors are not reliable sources of active omega 3 fatty acids.

. Clinical trials of fatty acid supplementation show higher dosages to be effective in achieving desired outcomes. Most fish oil supplementation occurs at ineffective dosages in liquids or plain soft gel capsules, where problems exist including: spontaneous decomposition of oils, inadequate bioavailability and poor patient compliance.

. Fish oil liquids and regular capsules have major disadvantages for the clinical use of fish oils. Enteric coating of fish oil capsules is to be preferred and this dosage form has made many regular fish oil supplements obsolete.

. Enteric coating can be undertaken with a targeted delivery system where the active omega 3 fatty acids, EPA and DHA, are protected from the destructive hydrolysis of fatty acids in the stomach and delivered to their site of maximal absorption in the small intestine.

. Targeted delivery of omega 3 fatty acids was introduced into the U.S. supplement market in 1992 by Holt MD Labs. This technology has been utilized or copied by several supplement and drug manufacturers. Targeted delivery of fish oil may substantially increase the bioavailability of active, omega 3 fatty acids.

. Successful therapeutic studies of fish oil in the treatment of inflammatory disease, published in peer-reviewed medical literature, have utilized enteric-coated fish oil with targeted delivery. These studies describe the ability to give high dosage fish oil with good patient compliance.


EPA/DHA (n-3, polyunsaturated fatty acids, PUFA) have shown benefit or beneficial actions in coronary heart disease, inhibition of platelet aggregation, reduction of cardiac arrhythmias, reduction of sudden death from heart attack, maintenance of vascular patency (especially after coronary bypass surgery), variable normalization of blood lipids, anticancer effects (especially breast and colon), improvements in cognitive function or neurodevelopment, antidepressant effects, support of insulin function, benefits in inflammatory disease e.g. rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other disorders such as asthma, acute respiratory distress, acute psoriasis, multiple sclerosis, certain allergies and dysmenorrhea. Despite a plethora of research, fish oil is not permitted to carry any firm treatment law. A compelling argument is for every adult in industrialized communities to supplement their diet with fish oil due to a common deficiency of omega 3 fatty acids in western diets.

IMPORTANT TECHNICAL CONSIDERATIONS Therapeutic effects of omega 3 fatty acids supplementation cannot be achieved consistently with dietary change (e.g. the Zone) or the use of ALA precursors (flax etc.) ALA may be not more than 2% convertible to EPA or DHA over a 24-hour period in some individuals; and this conversion is impaired by alcohol, saturated or trans-fatty acid intake, caffeine, diabetes mellitus or Metabolic Syndrome X and advancing age. Co-factors, e.g. Vitamins B3, B6, Mg, Zn and Vitamin C are required for optimum essential fatty acid metabolism.

Clinical EPA/DHA ForteT, special enteric-coated delivery of high potency Omega 3 support is a preferred dietary supplement for use by professional healthcare practitioners.



Servings Per Container: 30

Serving Size: 2 Softgels contain:

  • Pleomorphic Fish oil   2000 mg
    • (from sardine, anchovy, salmon, herring)
  • EPA (Eicosapentaenoic Acid)     600 mg
  • DHA (Docosahexaenoic Acid)    400 mg
  • Calories from Fat    20

Other ingredients: Gel capsule with polymer enteric coat.

 Cholesterol Free.

There are no reviews, yet! If you've tried this item, share your experience.

Only registered customers can review items. Please sign in to review!
Please register/login first.
The cookie settings on this website are adjusted to allow all cookies so that you have the very best experience. If you continue without changing your cookie settings, we'll assume that you are happy to receive all cookies on our website. However, if you would like to, you can change your settings at any time using the Change cookie settings link in the Special menu.